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Variation ofhormonal receptor, pS2, c-erbB-2 and GSTi contents in breast
carcinomas under tamoxifen: a study of 74 cases
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Summary Seventy-four post-menopausal patients with primary non-metastatic invasive ductal carcinomas of
the breast were first treated with tamoxifen alone (30 mg p.o. daily) for 5 months. To study changes induced by
tamoxifen, core biopsies before treatment and surgical specimens after hormonal therapy were assayed by
immunohistochemistry for oestrogen (ER) and progesterone receptors (PR), pS2, GSTh and c-erbB-2. After
tamoxifen, ER and PR significantly decreased in 60 and 44 cases respectively, whereas 11 and 19 cases showed
no variation and 2 and II cases showed an increase (P< 10-4). GSTir and pS2 showed a significant increase in
43 and 41 cases, a decrease in 2 and 21 cases and no variation in 29 and 12 cases (P<.10-4 and P=0.04
respectively). c-erbB-2 showed no significant variation under tamoxifen, increased in only three cases and
decreased in 13 cases. No relation was found between these variations and efficiency of hormone therapy. Our
results allow a better knowledge of protein expression modifications occurring in breast cancer cells under
tamoxifen therapy. They are also more consistent with clone selection rather than with phenotype modification.
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Antioestrogens are now widely used in the management of
breast cancers, either as adjuvant therapy or more recently as
neoadjuvant therapy. These drugs are of particular interest
and importance because of their clinical relevance, improving
survival of breast cancer patients (Early Breast Cancer
Trialist's Collaborative Group, 1992). They are also
remarkably well tolerated.
They act mostly through the oestrogen receptor system
(Katzenellenbogen et al., 1985), but the exact mechanism of
their anti-tumoral effects is not completely understood. A link
between the presence of oestrogen receptor in breast tumours
and response to endocrine therapy has been demonstrated,
but the prediction needs to be improved by additional
factors. In order to understand better the mode of action and
mechanism of resistance to endocrine therapy, a better
knowledge of biological changes arising under tamoxifen is
warranted. Although several studies exist in vitro, only a few
papers deal with changes occurring in vivo, in hormonal
receptor content and oestrogen-related proteins of breast
carcinomas following tamoxifen administration (Allegra et
al., 1980; Waseda et al., 1981; Taylor et al., 1982; Hull et al.,
1983; Melchor et al., 1990; Leroy et al., 1991).
In a first work (Soubeyran et al., submitted) we have
studied a group of post-menopausal breast carcinoma
patients first treated by neoadjuvant hormonal therapy
(tamoxifen). Using immunohistochemistry (IHC) on pretreat-
ment core biopsies, we have investigated the value of
oestrogen receptor (ER), progesterone receptor (PR) and
three oestrogen-related factors [pS2, glutathione S-transferase
isoenzyme (GSTi), and the oncogene c-erbB-2] as markers
of hormone responsiveness. pS2, a small cysteine-rich protein
of unknown function, appeared with ER to be strongly
correlated with tamoxifen-induced tumour regression. This
had already been suggested by others (Henry et al., 1989,
1991; Schwartz et al., 1991; Hurlimann et al., 1993; Wilson et
al., 1994). We were unable to show a link between response
to tamoxifen and c-erbB-2 or GSTi expression, contrary to
previous studies (Wright et al., 1992; Nicholson et al., 1993;
Dorion-Bonnet et al., 1993).
In an attempt to understand more fully tamoxifen's
molecular effects, we investigated pretreatment biopsies and
post-treatment tumours in a group of patients operated on
after 5 months of tamoxifen therapy. Immunohistochemical
changes of matched pairs specimens were studied and
compared with tumour response.
Materials and methods
Patients and tumours
We have described elsewhere a group of 208 post-menopausal
patients with primary non-metastatic invasive ductal breast
carcinomas treated in the Institut Bergonie between 1984 and
1990 by neoadjuvant hormonal therapy (Soubeyran et al.,
submitted). All 208 patients underwent a core biopsy before
treatment. Patients were staged according to the UICC TNM
classification. Oestrogen and progesterone receptor status was
initially determined by the dextran-coated charcoal method
(DCC) with a cut-off level of 10 and 15 fmol mg-' of
protein, respectively.
Patients received 30 mg tamoxifen daily for 5 months.
Tumour response was evaluated at this time by clinical
examination and the secondary treatment was decided upon
by a multidisciplinary team. After 5 months of tamoxifen 74
of the 208 women were operated on, either by Patey
mastectomy (n=37) or by wide local excision (n=37) with
axillary node dissection. Among them, five showed progres-
sive disease (PD), 13 static disease (SD), 23 a partial response
<50% (PR <50%), 30 a partial response >.50% (PR
.50%) and three a complete remission (CR).
Before immunohistochemical proceedings, pretreatment
core biopsies were reviewed to check tumoral cellularity
and graded, using the Scarff-Bloom and Richardson (SBR)
method. Post-treatment tumours were also reviewed for
selection of representative blocks.
Immunohistochemistry
Assay procedures Immunohistochemical studies for ER, PR,
pS2, GSTir and c-erbB-2 were carried out on pretreatment
core biopsies and on post-treatment tumours as previously
described (de Mascarel et al., 1996; Soubeyran et al., 1995;
Quenel et al., 1995). In summary, ER assay was done with a
mouse monoclonal antibody clone 1D5 (Dako), diluted 1:25
and applied for 45 min at room temperature. PR rat
monoclonal antibody (Abbott) was diluted 1:10 and applied
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overnight at room temperature. The monoclonal antibody
Histocis pS2 (Cis Bioindustries, France) was diluted 1:10 and
applied overnight at 4°C. For c-erbB-2 determination we used
a rabbit polyclonal antibody (Dako) diluted 1:600 and
applied for 10 min at room temperature. Dr K Cowan very
kindly provided us with a rabbit polyclonal antibody anti-
GSTxr which was diluted 1:3000 and applied for 2 h at room
temperature.
Bouin-Holland-fixed paraffin-embedded sections were cut
and mounted coated with 3'-aminopropyltriethoxysilane. For
hormonal receptor assays, sections were pretreated by
immersing in citrate buffer (0.01 M, pH 6) and heating at
high power in a microwave for two periods of 5 min. The
streptavidin-biotin-peroxidase method was performed
according to manufacturer's instructions with the Strept
ABComplex/HRP Duet Kit (Dako) for hormonal receptors
assays and with the LSAB Kit (Dako) for pS2, c-erbB-2 and
GSTx assays. Finally, sections were reacted with DAB for
5 min, rinsed and counterstained with fast green for
hormonal receptors and with hematein for other antibodies.
Appropriate control slides, positive and negative cases, were
included in each series.
Validity of assays To assess the validity of immunohis-
tochemistry (IHC), each of the five assays was prospectively
compared in a series of recent infiltrating breast carcinoma
cases, to one or more standard techniques. For pS2 and c-
erbB-2, these results have been previously reported
(Soubeyran et al., 1995; Quenel et al., 1995). For hormonal
receptors, the comparison was made in 103 cases. ER and
PR IHC assays done on paraffin sections were compared
with ER and PR DCC assays, and with IHC assays done
on frozen sections with the monoclonal antibodies ER
(H222) and PR from Abbott. For GSTx, a comparison was
made in 73 cases between IHC assay and dot-blot mRNA
analysis.
Evaluation ofthe series IHC analysis was performed without
knowledge of clinical data or outcome. An evaluation of
semiquantitative staining features was made, by noting the
percentage of positive infiltrating tumour cells and the
staining intensity. The percentage of positive infiltrating
tumour cells was estimated from the whole section and it
ranged from 0 to 100%. The intensity of staining was
subjectively scored on a 0-3+ scale, with 1 representing
faint but distinct staining, 3 representing intense staining and
2 an intermediate level. For each case, a score was obtained
by multiplying the percentage ofpositive cells by the intensity
(range: 0 to 300). Thresholds of positivity were predefined as
described previously (Soubeyran et al., submitted).
Statistical analysis
Sensitivity, specificity and agreement between current
immunohistochemistry and standard techniques were calcu-
lated for each assay.
Results were analysed using the Student's t-test and a
range of non-parametric tests (X2 test, Wilcoxon test and
Wilcoxon matched-pairs signed-rank sum test). Modifications
of immunostaining in post-treatment tumours compared with
matched pretreatment biopsies were studied. For each case
the difference in immunostaining (diff. X) was calculated
following diffi =Xi (after) -Xi (before). Diff. X=0 meant no
change of staining, diff. X<0 meant a decrease of positivity
after treatment, diff. X>0 meant an increase of staining.
Then, for each marker the hypothesis Ho =diff.i =0 was
studied, using the Wilcoxon test. Correlation between diff X
and response to endocrine therapy was tested by the
Wilcoxon test for each marker.
Results
The whole analysis was performed analysing the data by
percentages and scores. The results were similar with both
systems therefore for simplicity, only percentage results are
presented.
Validity of assays
Comparing the ER IHC paraffin assay with DCC and to IHC
frozen assays, we found an overall agreement of 89.3% and
88.3%, a sensitivity of 92.6% and 91.3% and a specificity of
82.8% and 80% respectively. An analysis of discrepancies
between assays showed five cases DCC positive/IHC paraffin
negative, with low levels of DCC positivity (four between 10
and 14 fmol mg-1, one of42 fmol mg-' ofprotein). Six cases
were DCC negative/IHC paraffin positive, with IHC values
ranging from 10 to 70% of positive cells. Six cases were IHC
paraffin positive/IHC frozen negative (values ranging from 10
to 50%) and six cases IHC paraffin negative/IHC frozen
positive (values ranging from 30 to 70%). Agreement between
DCC and IHC frozen assays was similar (87.4%), with six
cases DCC positive/IHC frozen negative (values ranging from
10 to 22 fmol mg-' ofprotein) and seven cases DCC negative/
IHC frozen positive (values ranging from 15 to 70%). The
comparison ofthe PR IHC paraffin assay with DCC and IHC
frozen assays showed an overall agreement of 90.3% and
95%, a sensitivity of 98% and 95% and a specificity of 83%
and 95.5% respectively. For GSTx, the agreement was of
78%, sensitivity 100% and specificity 71%.
Characteristics ofpatients and tumours: comparison with the
group of non-operated patients
Before studying variation of markers under tamoxifen
treatment, we wanted to ensure that our group of 74
patients who underwent surgery was not overselected, so we
first compared it with the remaining group of 134 patients
who did not undergo surgery. The results of clinical
parameters are listed in Table I. Except for age, which was,
as expected, a little higher in the non-operated group, all
other variables were not significantly different between the
two groups. Furthermore, there was no significant differences
in terms of response to endocrine therapy. Similarly, no
statistical differences were observed between the two groups
with respect to immunohistochemical parameters in core
biopsies either by x2 test or by Wilcoxon test (Table II).
Variation of marker status after tamoxifen therapy in the
surgery group
Variation in ER and PR status evaluated by immunohisto-
chemistry Hormonal treatment caused a decrease in both
ER and PR receptor contents, as shown by their distribution
before and after treatment. Before tamoxifen, 63 cases (85%)
were positive for ER compared with 19 cases (26%) after
treatment. Concerning PR, 50 cases (68%) were positive
before treatment compared with 36 cases (49%) after
tamoxifen. Immunostaining before and after tamoxifen for
a single case are represented in Figure la and b (ER) and Ic
and d (PR). Differences in the percentage of stained tumour
cells for matched pairs specimens, diff.ER and diff.PR, are
represented by histograms in Figures 2 and 3 respectively.
Diff.ER significantly decreased (P< 10-4), ranging from
-100 to +20 with a median value of -50. Of 11 initially
ER-negative tumours (< 10%) called the ER-negative group,
ten showed no variation and one decreased slightly
(diff.ER= -5). Among the 63 initially ER-positive tumours
(> 10%) called the ER-positive group, one tumour was not
evaluable for technical reasons, one remained unchanged and
two showed a slight increase (+10 and +20), whereas the
remaining 59 cases showed a significant decrease (from -10
to - 100). Fifty-one tumours were evaluated by the DCC
assay both before and after treatment. We observed a
decrease in 40 cases (-2 to - 636 fmol mg-'), no change
in three and an increase in eight cases (+ 6 to
+77 fmol mg-').
Although significantly decreasing (P< l0-4), diff.PR
demonstrated a more irregular behaviour: 19 tumours
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Table I Comparison of the surgery group vs no surgery: clinical parameters
Patients with Patients with no
surgery (n= 74) surgery (n= 134) P-value
Mean age (years) 68.2 ±9 (48-89) 74.6 ±8.9 (54-89) a<0.001
Nodal status
<NIB 49 (66%) 72 (54%) bNS (0.11)
,N1B 25 (34%) 62 (46%)
Median tumoral 40 (20-120) 45 (15- 160) CNS (0.36)
diameter (mm)
ER (DCC)
7 (10%) 21 (16%)
+ 66 (89%) 110 (82%) bNS (0.28)
unknown 1 (1%) 3 (2%)
PR (DCC)
25 (34%) 56 (42%)
+ 46 (62%) 70 (52%) bNS (0.26)
unknown 3 (4%) 8 (6%)
Histological grade
1 13 (18%) 27 (20%)
2 46 (62%) 71 (53%) bNS (0.42)
3 15 (20%) 36 (27%)
Response to
endocrine therapy
CR 3 (4%) 56 (43%) bNS (0.12)
PR-50% 30 (40%) 75 (57%)
PR<50% 23 (31%) 27 (75%)
SD 13 (18%) 20 (15%)
PD 5 (7%) 10 (7%)
a Student's t-test. b Chi-square test. c Wilcoxon test.
Table II Comparison of the surgery group vs no surgery: immunohistochemical parameters on core biopsies
Patients with Patients with no P-value
surgery (n= 74) surgery (n= 134) Chi-square test Wilcoxon test
ER <10% 11 (15%) 25 (19%)
>10% 63 (85%) 109 (81%) NS (0.61) 0.19
PR <10% 24 (32%) 53 (40%)
>10% 50 (68%) 81 (60%) NS (0.38) 0.43
pS2 <3% 23 (31%) 32 (24%)
>,3% 51 (69%) 102 (76%) NS (0.33) 0.34
c-erbB2 =0 55 (74%) 87 (65%)
>0 19 (26%) 47 (35%) NS (0.21) 0.19
GSTr =0 39 (53%) 74 (55%)
>0 35 (47%) 60 (45%) NS (0.83) 0.94
showed no variation, 11 of them showed an increase and a
decrease was observed in the remaining 44 cases. The median
value was -25 (extremes:-95 to + 55). Looking at
variations on the two subgroups of ER-negative and ER-
positive tumours, we noted that in the former, three cases
showed no variation in PR content, one case increased
(diff.PR = +25) whereas seven cases decreased from -5 to
-70. In the ER-positive group, 16 cases showed no
variation, ten cases increased from + 1 to + 55 and 37
decreased from -2 to
-95.
Variation in GSTi and pS2 contents We observed an
increase of both GSTir and pS2 contents after hormone
therapy. For GSTir, we noted that before treatment 53% of
cases were negative against 31% after treatment. An
example of immunostaining before and after tamoxifen in
a single case is shown in Figure 1 e and f. Analysing
diff.GSTx (Figure 4) we observed that, whereas 29 cases
showed no variation and two decreased slightly, 43 tumours
showed an increase ranging from 1 to 100. These variations
were statistically significant (P< 10-4). The median value
was + 10 with extremes ranging from -10 to + 100. In the
ER-negative group, five tumours did not vary and six
increased after tamoxifen (diff.GST7r ranging from + 10 to
+ 30). In the ER-positive group, two tumours decreased
(diff.GSTn = - 10), 24 remained stable and 37 increased
from +1 to +100.
Analysis of pS2 distribution indicated less striking
variations: 31% of cases negative (less than 3% of
positivity) before tamoxifen against 23% after. An example
of immunostaining in a single case is represented in Figure ig
and h. Differences in matched pairs specimens (diff.pS2) are
shown in Figure 5. Twelve cases showed no variation whereas
21 cases decreased from -1 to -65 and 41 cases increased
from + 1 to +95. The median value of diff.pS2 was + 2, with
extremes ranging from -65 to +95 (P = 0.04). In the ER-
negative group three tumours decreased (diff.pS2 ranging
from -2 to -25), two showed no variation and eight
increased (from + 1 to +39). In the ER-positive group 18
cases decreased (from -2 to -65), ten remained stable and
35 increased from + 1 to + 95.
Variation in c-erbB-2 content Distribution of c-erbB-2
before and after treatment showed a high percentage of
negative tumours: 74% and 81% respectively. A histogram of
matched pairs specimens (Figure 6) showed that c-erbB-2 was
not significantly modified by hormonal treatment in the
majority of cases (58/74), P = 0.11. The median value of
diff.c-erbB-2 was 0 (extremes: -50 to + 75. Only one of the
58 initially c-erbB-2-negative cases, showed a slight increase
under tamoxifen (diff.c-erbB-2 = +20) and it was an ER-
positive tumour. Focusing on the 19 remaining cases which
were initially positive, there was a tendency overall to
decrease (P =0.07). Four tumours showed no variation
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under tamoxifen and two increased (+ 50 to +75). Both were
ER-positive tumours. Thirteen tumours showed a decrease,
of which four were ER negative and nine ER positive.
Variations in marker status and clinical response
We subdivided our group of operated patients according to
response to endocrine therapy as defined above in Materials
and methods. Fifty-six patients were in the group of
responders (CR+PR>50%+PR<50%) and 18 in the
group of non-responders (SD +PD). To study whether
changes in markers correlate with response, the Wilcoxon
test was done. There was no statistical difference in marker
variations (diff.X) between the two subgroups (ER: P=0.63;
PR: P=0.62; pS2: P=0.43; GSTir: P=0.24; c-erbB-2:
P=0.88). In addition, combined patterns of marker
variation have been studied in the different clinical
subgroups. Multiple kinds of combinations were observed
which did not allow us to distinguish any discernible pattern.
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Figure 1 Differences in immunostaining before (a, c, e, g) and after (b, d, f, h) tamoxifen therapy for matched pairs specimens. ER
(a and b): there is an obvious loss ofimmunostaining. PR (c and d): only a few tumour cells immunostained after tam. GSTir (e and
f): immunostaining strongly increased after tam. pS2 (g and h): a higher percentage of cells are strongly immunostained after tam.Among the 5 cases showing progressive disease three were
ER/pS2-positive and c-erbB-2 negative before treatment,
becoming ER negative after. c-erbB-2 remained unchanged.
Two showed a decrease of pS2 positivity and one an increase.
One was PR negative/GSTn positive remaining unchanged.
The two others were PR-positive/GSTir negative. One
showed increasing PR and GSTir positivity. The other
remained GSTir negative and showed a decrease in PR
content. The two remaining cases were as follows: one was
a,
a)
a)
n
0
0
.0
E
z
15
D
~~~~~~
SE F ¢ /
No t^fo "so F£
Median value = -50
Figure 2 Differences before and after
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negative for all markers except PR which was slightly
positive. All markers remained unchanged under tamoxifen.
The other one was ER/PR/pS2 negative and GSTr/c-erbB-2
positive and remained stable for ER, PR, pS2 and GSTrr,
whereas c-erbB-2 showed a decrease of positivity.
There were 13 cases with stable disease. One was ER/pS2
negative and PR/c-erbB-2/GSTar positive showing no change
for ER and pS2, a decrease ofpositivity for PR and c-erbB-2
and an increase for GSTx. Twelve were ER positive/c-erbB-2
negative, except one slightly c-erbB-2 positive (5%), before
treatment. All showed a decrease in ER positivity and were c-
erbB-2 negative after treatment. One of 12 was PR/pS2/GSTx
negative, remaining negative for PR and GSTr and showing
a slight pS2 positivity after treatment (5%). Two were PR
negative/pS2 positive with one GSTi positive and the other
GSTx negative. They remained PR negative while we
observed an increase in GSTx immunostaining. One showed
an increase in pS2 staining, the other a decrease. In the whole
group assessed, 9/12 were PR positive and showed a decrease
in positivity under tamoxifen. Of the nine, seven were pS2
positive showing unchanged, increased and decreased staining
in two, four and one case respectively. Two were and
remained pS2-negative. Of the nine PR-positive cases, two
were and remained GSTi negative, seven were GSTx positive
with five showing increased staining and two no change.
In the group of responders, 23 showed a partial response
<50% and 30 a response >50%. Twenty-one cases were
ER/PR/pS2 positive before tamoxifen. Ten showed a
decrease of ER, PR and pS2 staining after treatment. We
observed a decrease in both PR and ER in six cases whereas
pS2 staining remained stable in three cases and increased in
15
10 _
5
0
a,
a1)
(a
C.)
0
t-
.0
E
z
Ir bs , o q
Nx>,° Nta,° O>,° ,NI
MedianNvalue=-17.5 Diff.PR(%)
Median value = -17.5 Diff. PR (%)
Figure 3 Differences before and after tamoxifen therapy;
Diff. PR=PR% (after)-PR% (before)
30
25
20
15
110
5
I(O N IV 0 0 14.'
I\41. IT
Median value = +2
Figure 5 Differences before a
Diff.pS2=pS2 (after)-pS2 (befor4
Diff. pS2 (%)
nd after tamoxifen therapy;
30
25
20
15
10
5
0
cn
a)
CO)
o
0
.0
E
z
N
0
l N0
\
N0
i
r''t; (~'~
Median value = +10 Diff. GSTic (%) Median value = 0 Diff. ErbB-2 (%)
Figure 4 Differences before and after tamoxifen therapy;
Diff. GSTn=GSTx (after)-GSTx (before)
Figure 6 Differences before and after tamoxifen therapy;
Diff. Erb-B-2=Erb-B-2 (after)-Erb-B-2 (before)
a)
a)
C.) m
0
.0
E
z
a) a)
ax C.)
0
a)
.0
E
z
Nf 20 F
_
1(
(
-
_
_-
1-
I I ///A
Ir10 IN IVI 0
0 lo.' le I
v -j
20 F/////]
077,17M
I
v
ovlzm F,7a??Mg///Marker variation under tamoxifen
Soubeyran et al
three others. In one case, ER staining decreased while PR
and pS2 staining increased. In six cases, ER staining
decreased and pS2 increased whereas PR staining decreased
in three of six and remained unchanged in the three
remaining. Finally, in one case ER positivity showed no
change whereas PR staining decreased and pS2 increased.
Ten cases were ER/PR positive/pS2 negative. All showed a
decrease in ER and PR staining in post-treatment tumours.
In seven cases, pS2 became positive and three tumours
remained negative.
Twelve cases were ER/pS2 positive and PR negative. PR
remained negative in nine cases and showed increased
positivity in three, which also showed increased pS2 and
decreased ER positivities. In four of nine cases ER showed a
decrease whereas pS2 increased in post-treatment specimens.
In three of nine cases, pS2 showed no change whereas ER
decreased in one case, increased in another and was not
evaluable in the rest. In the last two cases, ER and pS2
staining decreased.
Four cases were ER negative and PR/pS2 positive. After
therapy, all remained ER-negative and became PR negative
while pS2 showed a decrease in two cases and an increase in
the others.
The remaining six cases were as follows: one case was ER/
PR negative and pS2 positive showing no change of ER and
PR while pS2 staining increased. One case was ER/pS2
negative and PR positive. ER remained negative while pS2
became positive and PR decreased. Two cases were ER/PR/
pS2 negative in pretreatment biopsies. One case showed a
positivity of PR in post-treatment tumours and the other a
positivity of pS2. Finally two cases were ER positive and PR/
pS2 negative. One became ER negative and PR/pS2 positive
after treatment. The other showed a decrease in ER
positivity, whereas PR and pS2 remained unchanged.
Of these 53 cases, 24 were GSTi positive and 29 GSTi
negative. Thirty-three showed an increase in immunostaining,
whereas 19 showed no change and one a decreased positivity.
Relative to c-erbB-2, 14 cases were positive and 39 negative.
Forty-one cases showed no change while nine cases showed a
decreased and three an increased immunostaining.
Lastly, a complete remission was observed in three cases.
All were ER positive and showed a decrease of ER staining
after tamoxifen. One of three was PR positive/pS2-negative/
GST7r negative/c-erbB-2 negative. This phenotype remained
unchanged after treatment. Another was PR negative/pS2
positive/GSTn negative/c-erbB-2 positive before treatment
and showed no changes except a slight decrease (-5) of pS2
staining. The last one was PR/pS2 negative and GST7r/c-
erbB-2 positive and showed an increase of immunostaining
for PR, pS2 and GSTx, whereas c-erbB-2 became negative.
Discussion
Antioestrogens, like other anti-tumour drugs, are suspected
to have effects on the expression of various proteins in cancer
cells. These are often difficult to evaluate because their study
by well-known reference techniques, such as biochemistry,
radioimmunology or molecular biology, requires a relatively
large amount of fresh material. On the contrary, immuno-
histochemistry, with the availability of new and reliable
antibodies, is becoming more important through retrospective
studies. Using this latter technique, we observed significant
changes in protein expression in a group of patients first
treated by tamoxifen for 5 months and then operated on. We
generally found that under tamoxifen, hormonal receptors
decreased while GST7r and pS2 expression increased and c-
erbB-2 remained stable. Our data concern a retrospective
group of patients with perforce selection biases. However, on
comparing a range of criteria between this group and the
group of non-operated patients, we failed to reveal the bias.
A high percentage of ER-positive tumours was observed in
both groups. In fact, most of the patients who entered
neoadjuvant tamoxifen therapy had a receptor-positive
tumour, otherwise they preferably underwent other therapy.
The reliability of a single biopsy for determining gene
expression has been questioned. The problem of the tumour
sampling was particularly great as gene expression is
frequently heterogeneous throughout the tumour and
between primary and metastatic sites (Holdaway et al.,
1983). However, in spite of this heterogeneity, Hull et al.
(1983) and Allegra et al. (1980) observed only 3% and 15%
of major discordances, that is one assay positive and the
other one negative between simultaneous assays, respectively.
Moreover, provided that cellularity is sufficient, good
agreement is found between corecut biopsies or fine-needle
aspirates and surgical specimens with respect to HR status
(Mauriac et al., 1981; Katz et al., 1990; Frigo et al., 1995).
However, slight variations between core biopsies and surgical
specimens could certainly be ascribed to this intratumoral
heterogeneity.
Antioestrogens such as tamoxifen, have a tumoristatic
rather than a tumoricidal effect on breast cancer cells (Warri
et al., 1993; Rochefort et al., 1991). In the cell, they have two
sites of action. They chiefly compete with oestrogen to bind
on to oestrogen receptors, inducing conformational changes
of the receptor (Katzenellenbogen et al., 1985). They
additionally have high affinity for microsomial antioestrogen
binding sites (AEBS) to which oestrogens do not bind. These
AEBS are present in equal concentrations in breast cancer
cells whatever the ER status (Katzenellenbogen et al., 1985).
Antioestrogens have several molecular effects. They block
cells in G0-GI stage of cell cycle inducing the arrest of cell
proliferation (Sutherland et al., 1983). They also down-
regulate oestrogen-stimulated secretion of several specific
proteins (Horwitz et al., 1978; Kida et al., 1989; Daly and
Darbre, 1990; Chalbos et al., 1993; Warri et al., 1993). Some
of these effects are reversible by oestradiol (Lippman et al.,
1986; Gottardis et al., 1988; Daly and Darbre, 1990). A
recent report has suggested that the growth-inhibitory effects
oftamoxifen may be explained in part by its ability to disrupt
a complex between ER, ERAP160 (an ER-associated protein
supposed to mediate oestradiol dependent transcriptional
activation) and other factors necessary for transactivation
(Halachmi et al., 1994). Consequently, ER-positive (ER+)
breast cancer cells are more likely to respond to antioestrogen
than ER-negative (ER-) breast cancer cells (Katzenellenbo-
gen et al., 1985). In fact, endocrine therapy affects the
proliferation of both ER+ and ER- cells, clones of the
human breast cancer cell line MCF-7 (Noguchi et al., 1990).
Human breast cancer cells also secrete growth factors. In
hormone-dependent cells, several are oestrogen-regulated,
whereas in cells which acquire independence they are
constitutively increased (Lippman et al., 1986). Further-
more, the antioestrogenic properties and the antigrowth
factor effects of antioestrogens can be dissociated, thus
indicating that the latter is not a direct consequence of the
former (Chalbos et al., 1993). Additionally, antioestrogens
such as tamoxifen, behave as a partial agonist-antagonist,
depending on the target tissue (Gottardis et al., 1988) and on
the nature of the gene (Berry et al., 1990). Moreover, it has
dual oestrogenic/antioestrogenic properties, being dose
dependent (Horwitz et al., 1978) and time-dependent
(Waseda et al., 1981; Melchor et al., 1990; Vering et al.,
1993). At lower doses or short-term administration (1-2
weeks) tamoxifen may be oestrogenic whereas at higher levels
or long-term administration (>3-4 weeks) the antioestro-
genic properties are observed.
In vitro and in vivo studies in breast cancer cells have
shown, in accordance with our IHC results, a decrease of ER
content following long-term antioestrogen therapy (>3
weeks) (Allegra et al., 1980; Waseda et aL., 1981; Taylor et
al., 1982; Holdaway et al., 1983; Melchor et al., 1990;
Noguchi et al., 1990). Likewise 78% of our tumours
evaluated by the DCC assay after tamoxifen therapy showed
a decrease in ER content. It is not excluded that tamoxifen
occupying ER sites may result in artificially low ER
measurements by DCC (Hull et al., 1983), but similar
results are obtained with different techniques such as IHC,
DCC and hydroxylapatite assays. A false negativity of theIHC assay (interference of tamoxifen with ID5 paraffin
assay), although not excluded, will imply complete masking
of antigenic epitopes. As demonstrated by Taylor et al., the
fall in ER content measured by the DCC assay, could also be
related to reduced cellularity of the specimen. This was true
in responding tumours. But this change was also observed in
non-responding tumours where cellularity was infrequently
reduced (Taylor et al., 1982). Using the IHC technique, the
cellularity of the specimen, provided that sufficient material
was examined to be representative of the tumour, could not
be responsible for the change of ER content since results are
done in terms of percentage of tumour cells. In our group of
progressive disease, three of five tumours showed pretreat-
ment high ER-positivity and were completely negative after
treatment with a high post-treatment cellularity. Excluding
these possibilities of false negativity, molecular effects of
tamoxifen should be considered. Paradoxically, antioestro-
gens do not prevent oestrogen receptor synthesis nor do they
accelerate or block ER degradation in MCF-7 cells
(Katzenellenbogen et al., 1985). As already noted by Allegra
et al. (1980), this could suggest that hormonal therapy
selectively eliminated ER + cells. So the clear reduction of
ER content in tumours under tamoxifen could be at least in
part consistent with the disappearance of ER-positive clones
and/or the development of ER-negative clones, rather than
with the disappearance of ER expression within cells
themselves.
This hypothesis is consistent with our findings concerning
variations of PR under tamoxifen treatment. We found a
significant decrease of PR under tamoxifen, but close analysis
of the results showed a more irregular behaviour. Whereas
59% of our tumours lost some or all of their PR expression,
26% showed no variation and 15% an increase. This has
previously been observed by other authors in a short series of
14 patients (Melchor et al., 1990). An in vitro study showed
similar results: following oestrogen deprivation, some breast
cancer cell lines and their subclones behave differently,
showing a low level of PR (cell line ZR-75-1, clone 4), a
high level of PR (ZR-75-1, clone 11-A) or an unchanged level
(cell line T47D) (Daly and Darbre, 1990). Tamoxifen is
known to down-regulate PR through ER (Horwitz et al.,
1978). Thus, it is possible that tamoxifen (partially or
completely occupying ER sites) down-regulation of PR
through ER was not complete, especially in non-responding
tumours. However, in the hypothesis of cloned selection by
tamoxifen, either negative or positive PR phenotypes could
also be encountered, more especially as cells lose oestrogen
receptors and so control of PR expression.
In vitro, pS2 expression is induced by oestrogen
(Masiakowski et al., 1982; Jakowlew et al., 1984; Kida et
al., 1989; Daly and Darbre, 1990) and this effect is reversible
either by oestradiol withdrawal or antioestrogen therapy
(Kida et al., 1989; Warri et al., 1991, 1993) resulting in a
decrease in pS2 level. But antioestrogens alone, i.e. in the
absence of oestrogen, have no effect on pS2 level (Kida et al.,
1989). So, although we expected a decrease, we noticed on
our series of tumours a relative increase of pS2 expression
following tamoxifen administration. Indeed, 12 cases showed
no variation and 25 cases showed little variation (approxi-
mately 10%). Thus, contrary to in vitro studies, our results in
vivo suggest that pS2 regulation depends on other additional
non-oestrogenic mechanisms that may be activated by
tamoxifen. They could also reflect acquisition or develop-
ment of a clone with a hormone independent phenotype.
Briinner et al. (1993) showed that the latter is associated with
modifications in the expression of some oestrogen-regulated
genes while ER expression itself remains stable. For instance,
these modifications were an increase in pS2 mRNA level
while the PR level was variable. Under tamoxifen therapy, an
increase in the expression of some growth factors has also
Marker variation under tamoxifen
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been reported. For example, transforming growth factor
(TGF-,B) has a growth-inhibitory effect and is stimulated by
antioestrogen (Lippman et al., 1986; Daly and Darbre, 1990).
The pS2 protein is suspected to have a growth factor function
(Rio et al., 1988; Jakowlew et al., 1984). However, it is not
involved in the growth-stimulatory effect of oestrogen (Kida
et al., 1989). If its increase reflects acquisition ofthe hormone
independent phenotype, we should find a relationship with
the response to endocrine therapy. We failed to demonstrate
any significant relationship, which suggests that the mechan-
isms of resistance are complex.
A significant increase in GSTi expression was observed
following tamoxifen treatment. GSTx gene is highly
expressed in ER-negative breast cancer cell lines (Morrow
et al., 1992) and tumours (Howie et al., 1989; Moscow et al.,
1988; Gilbert et al., 1993). Comparing ER- and ER' cell
lines, Morrow et al. (1992) showed that endogenous GSTi
gene transcription rates are similar in both cell lines but the
stability of endogeneous GSTi mRNA is extraordinarily
higher in ER-negative cells. Apart from a direct or indirect
effect of tamoxifen on gene regulation, this possible post-
transcriptional mechanism could explain our results. As
tumours gain in ER-negative cells, they gain in GSTr
expression by increased stability of mRNA.
In the ER+ T47D and ZR-75-1 cell lines (Dati et al.,
1990; Warri et al., 1991; Le Roy et al., 1991) oestrogens
down-regulated the expression of c-erbB-2 and this effect
could be reversed by antioestrogens (Read et al., 1990; Warri
et al., 1991). On the other hand, no effect of oestradiol on c-
erbB-2 RNA could be observed in ER- cell line (Le Roy et
al., 1991). Moreover Le Roy et al. (1991) and Warri et al.
(1991) failed to demonstrate an effect of antioestrogens on c-
erbB-2 expression in breast cancer cell lines grown in a
steroid-deprived medium (without oestrogen). In vivo studies
showed conflicting results. In nude mice (Warri et al., 1991)
tamoxifen treatment was associated with enhanced expression
of c-erbB2 and growth arrest. This is surprising since
amplification and overexpression of c-erbB-2 usually corre-
late with poor prognosis and increased growth rate (Tsuda et
al., 1990; May et al., 1990; Toikkanen et al., 1992). In
contrast, the studies of Le Roy et al. (1991) showed lower c-
erbB-2 RNA levels in a tamoxifen-treated group of patients
in comparison with an untreated group, but only in a subset
of ER-negative tumours, whereas there was no difference in
the ER' group. In our study, no significant variations of c-
erbB-2 were observed under tamoxifen therapy. However,
only 19 of 74 tumours were initially c-erbB-2 positive. In this
subset with initially 80% of ER+ tumours, we observed a
decrease under tamoxifen close to significance (P=0.07). Our
results are more consistent with the data of Le Roy et al.
(1991) and with the development of an ER-negative clone.
A study of tamoxifen effects, in vivo, on breast cancer cells
should lead to a better understanding of antioestrogens'
mechanism of action. It should lead to the definition of
hormone-sensitive and resistant criteria. Althoug no definite
relationship was demonstrated between marker variations
and response to endocrine therapy, we believe that
modifications observed under tamoxifen therapy favour
clonal selection. Further analyses are needed to address this
point in more detail.
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